FSB Premier Wealth Management Inc. Purchases 329 Shares of Elevance Health, Inc. (NYSE:ELV)

FSB Premier Wealth Management Inc. grew its position in shares of Elevance Health, Inc. (NYSE:ELV) by 13.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,844 shares of the company’s stock after buying an additional 329 shares during the quarter. FSB Premier Wealth Management Inc.’s holdings in Elevance Health were worth $1,049,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Fisher Asset Management LLC increased its holdings in Elevance Health by 3.8% during the 3rd quarter. Fisher Asset Management LLC now owns 838 shares of the company’s stock valued at $436,000 after purchasing an additional 31 shares in the last quarter. Public Sector Pension Investment Board increased its stake in shares of Elevance Health by 12.3% in the third quarter. Public Sector Pension Investment Board now owns 10,032 shares of the company’s stock valued at $5,217,000 after buying an additional 1,100 shares in the last quarter. Captrust Financial Advisors lifted its position in Elevance Health by 0.7% during the 3rd quarter. Captrust Financial Advisors now owns 38,974 shares of the company’s stock worth $20,267,000 after buying an additional 286 shares in the last quarter. Edgestream Partners L.P. bought a new stake in Elevance Health during the 3rd quarter worth about $532,000. Finally, Semmax Financial Advisors Inc. increased its position in Elevance Health by 5.5% in the 3rd quarter. Semmax Financial Advisors Inc. now owns 7,441 shares of the company’s stock valued at $3,869,000 after acquiring an additional 388 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Trading Down 0.0 %

Shares of NYSE ELV opened at $431.84 on Monday. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71. Elevance Health, Inc. has a twelve month low of $362.21 and a twelve month high of $567.26. The company’s fifty day moving average is $404.45 and its 200-day moving average is $420.42. The stock has a market cap of $98.18 billion, a price-to-earnings ratio of 16.86, a P/E/G ratio of 1.18 and a beta of 0.86.

Elevance Health (NYSE:ELV) last posted its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. Equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Investors of record on Monday, March 10th were paid a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a yield of 1.58%. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date was Monday, March 10th. Elevance Health’s dividend payout ratio is presently 26.71%.

Insider Buying and Selling at Elevance Health

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total value of $1,388,635.20. Following the sale, the executive vice president now owns 10,116 shares of the company’s stock, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the transaction, the chief accounting officer now directly owns 1,847 shares of the company’s stock, valued at $766,745.11. This represents a 19.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ELV. Cantor Fitzgerald reiterated an “overweight” rating and set a $485.00 target price on shares of Elevance Health in a research report on Friday, January 24th. Argus upgraded Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 price objective on the stock in a research report on Monday, March 17th. StockNews.com upgraded Elevance Health from a “hold” rating to a “buy” rating in a research report on Thursday, March 20th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Elevance Health in a report on Friday. Finally, Wells Fargo & Company dropped their price objective on Elevance Health from $483.00 to $478.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $519.81.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.